| Q28253637 | Addition of estramustine to chemotherapy and survival of patients with castration-refractory prostate cancer: a meta-analysis of individual patient data |
| Q37602299 | Chemotherapy in patients with castration-resistant prostate cancer |
| Q43056779 | Chemotherapy with docetaxel in prostate cancer. A case report |
| Q30245022 | Chemotherapy with or without estramustine for treatment of castration-resistant prostate cancer: A systematic review and meta-analysis |
| Q50915446 | Docetaxel in combination with estramustine and prednisolone for castration-resistant prostate cancer. |
| Q34165680 | Docetaxel with or without estramustine for estramustine refractory castration-resistant prostate cancer: a single institution experience |
| Q37721016 | Docetaxel-based combination therapy for castration-resistant prostate cancer |
| Q33397197 | Docetaxel-based therapy with or without estramustine as first-line chemotherapy for castration-resistant prostate cancer: a meta-analysis of four randomized controlled trials |
| Q38028012 | Docetaxel: a review of its use for the first-line treatment of advanced castration-resistant prostate cancer |
| Q46320855 | Estramustine plus docetaxel as second-line therapy in patients with hormone-refractory prostate cancer resistant to docetaxel alone. |
| Q90293688 | Incidence of fatigue and low-dose corticosteroid use in prostate cancer patients receiving systemic treatment: a meta-analysis of randomized controlled trials |
| Q39030381 | Intermittent docetaxel chemotherapy as first-line treatment for metastatic castration-resistant prostate cancer patients. |
| Q39982891 | Molecular targeting of Bcl-2 overcomes prostate cancer cell adaptation to XIAP gene downregulation |
| Q37473193 | Nanoformulation of natural products for prevention and therapy of prostate cancer |
| Q37957744 | Pharmacoethnicity of docetaxel-induced severe neutropenia: integrated analysis of published phase II and III trials. |
| Q37163139 | Phase I study of the safety and pharmacokinetics of trabectedin with docetaxel in patients with advanced malignancies |
| Q38639852 | The Emerging Role of Extracellular Vesicle-Mediated Drug Resistance in Cancers: Implications in Advanced Prostate Cancer |
| Q45943517 | The evolution of chemotherapy for the treatment of prostate cancer. |
| Q37901085 | The use of estramustine phosphate in the modern management of advanced prostate cancer |
| Q84355176 | Weekly low-dose docetaxel combined with estramustine and dexamethasone for Japanese patients with metastatic castration-resistant prostate cancer |